UniDoc to Unveil ‘H3 Cube’ at American Telehealth Conference

Remote health kiosk at innovation event in Boston May 1-3

VANCOUVER, BC, — (April 27, 2022) – UniDoc Health Corp. (CSE: UDOC) (FRA: L7T) (OTCQB: UDOCF) (“UniDoc,” or the “Company”), an innovator in the telehealth sector, is pleased to announce its participation and product launch at ATA2022, booth 1202, during the world’s largest telehealth innovation event held in Boston, Massachusetts May 1 to 3, 2022.

The event is produced by the American Telemedicine Association, which was founded in 1993 and is a non-profit association headquartered in Washington D.C. The ATA includes more than 400 organizations focused on transforming health and care through enhanced, efficient delivery. ATA2022 is the organization’s 26th Annual Conference & Expo where providers, technology developers, business professionals and leaders from across the healthcare sector convene to hold in-depth, thoughtful, and critical discussions about the future of health.

During this year’s event at the Boston Exhibition & Convention Center (BCEC) UniDoc Health will unveil the “H3 Cube” at its affiliate partner AMD Global Telemedicine Inc. booth 1202. The H3 Cube is a custom fabricated kiosk designed for telehealth delivery in commercial partner locations. Company representatives will be in attendance to elaborate upon UniDoc’s Virtual Care Solutions Model relative to business opportunities for potential licensees, medical practitioners, and insurers.

The customizable, and comprehensive H3 Cube telehealth solution integrates cloud-based services and analytical tools, along with access to the Company’s developing network of healthcare providers, pharmacies, and hospitals. The telehealth capability provides patients with a live virtual visit with a healthcare professional utilizing fully integrated medical devices within a controlled environment in locations such as pharmacies, community centres, or care facilities.

Company CEO & President Antonio Baldassarre notes, “We are excited to have this opportunity to come together with the telehealth community as we launch our new H3 Cube into the marketplace. Plus, a big thank you to our partners at AMD Global Telemedicine for hosting our launch during the event. We have worked hard to get to this point, and we hope to build upon our efforts through the introduction of our business to the association membership and beyond. We look forward to meeting up with many old friends and in meeting and making new relationships that will help propel UniDoc Health towards future commercial success.”

We invite anyone interested in our venture to visit our website at www.unidoctor.com and signup to receive the timely updates regarding our activities, events, and progress. You are also invited to join us on social media with Facebook, Twitter or Instagram.

On Behalf of The Board of Directors,

Sincerely,

~Antonio Baldassarre~

Antonio Baldassarre
CEO, President & Director
UniDoc Health Corp. (CSE: UDOC)

About UniDoc Health Corp. (CSE: UDOC) (FRA: L7T) (OTCQB: UDOCF)

UniDoc is developing a telehealth solution which is being designed as a self-contained remote virtual clinic within a private kiosk for patients to undergo full consultations as if they were present in a physician’s office. Telehealth opens the doors to a large segment of the population challenged by access, experience or understanding of online computer technology. It is the Company’s belief that physical accessibility is the key to its business proposition. UniDoc is dedicated to unlocking shareholder value by delivering an excellent product and sophisticated commercial network within an expedited timeframe. The UniDoc team encourages engagement, questions, and interest, so please stay in touch and invite anyone who might be interested in our story to visit our website at www.unidoctor.com and signup to receive the latest information with updates on our activities, events and progress. You are also invited to join us on social media with Facebook, Twitter or Instagram.

For further information, please contact

UniDoc Investor Relations
Tel: +1 778.383.6731
Email: info@unidoctor.com

Matt Chatterton, Director
Tel: +1 778.613.2082
Email: matt@unidoctor.com

Media Inquiries
media@unidoctor.com

Forward-Looking Statements

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the Company’s participation at ATA2022 and the commercial launch of the H3 Cube.

Forward-looking information is based on the assumptions, estimates, analysis, and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; the Company’s ability to secure additional financing on reasonable terms; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s  final prospectus dated December 2, 2021 under the heading “Risks Factors.” Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Sign Up For News Alerts

Enter your details below and we will add you to our News Alerts list.

Austin Thornberry

Director

Mr. Thornberry is a seasoned finance professional with a background in advising new companies in the venture capital market. He brings extensive experience working with high-growth companies across numerous industries through his past work in the technology and innovation banking group at the Bank of Montreal and in the financial services arm of Ernst & Young advising on multiple capital markets transactions. Mr. Thornberry has split his time working in Toronto, Ont., and Vancouver, B.C. He obtained his bachelor of commerce at McGill University and has held the CPA, CA, designation since 2019.

Matt Chatterton

DIRECTOR

Mr. Chatterton brings over 18 years of experience in development and execution of complex projects. His  expertise includes project management, facility management, logistics, and supply side processes and  procedures at a number of operations in Canada and internationally. He has  been involved in the public markets for the last three years managing IPO processes and transitioning  businesses to post listing operations. Mr. Chatterton is a Professional Engineer and graduate of  Canada’s Queens University with a Bachelor’s degree in Engineering Chemistry (2001) and Master’s degree in Chemical Process Engineering (2003).

Sina Pirooz

Director

Mr. Chatterton brings over 18 years of experience in development and execution of complex projects. His  expertise includes project management, facility management, logistics, and supply side processes and  procedures at a number of operations in Canada and internationally. He has  been involved in the public markets for the last three years managing IPO processes and transitioning  businesses to post listing operations. Mr. Chatterton is a Professional Engineer and graduate of  Canada’s Queens University with a Bachelor’s degree in Engineering Chemistry (2001) and Master’s degree in Chemical Process Engineering (2003).

Dr. Sazzad Hossain, PhD

Chief Scientific Officer

He is the former Chief Scientific Officer of InMed Pharmaceuticals Inc., a leading public Canadian bio-pharmaceutical company. Previously he worked as Senior Scientist at Biotechnology Research Institute of National Research Council Canada. Working with the Canadian government he helped establish the pharmacology laboratory to evaluate safety and efficacy of cannabinoid-based and other drugs under development for cancer, cardiovascular and ocular diseases.

Jacob Moshinsky

Chief Operating Officer

Jacob is the CEO & founder of MoviWear a GPS, fall down detection & remote vital-sign monitoring platform, alerting caregivers of real-time emergencies. Jacob is a communications and technology expert with over 15 years’ experience in the field. the NurtureWatch health monitoring Smartwatch and MoviWearMED remote vital sign monitoring platform Prior to MoviWear, Jacob worked in both the Canadian telecom and the CPG industry. He led the Product Development and Business Strategy team at TELUS for the Small Business Portfolio. Jacob also worked in various product and service management roles within Rogers Communications where he launched and managed wireless and wireline products.

Antonio Baldassarre

CEO, President and Director

Mr. Baldassarre has held senior management and director positions of new business start-ups and established multinational organizations with over 30 years of experience in the Security, Information Technology and Communications industries. With leadership skills in management of international operations, shareholder exit strategies, and overall business development, he has utilized a wide range of strategic programs to maximize organic growth into specific industry segments through OEM, alliances, and direct multi-level distribution channels.

Mr. Baldassarre is able to plan, organize and direct all aspects of a Corporation from Operations, P&L oversight, product distribution, Product promotions, sales and development activities and initiatives utilizing my extensive marketing/sales senior management experience with developed abilities in team leadership and program/campaign development. Directly involved in the growth, branding and ultimately optimizing market share, product awareness, revenues, profitability and shareholder value.

Mr. Baldassare is also the President of LRG Security Canada Inc. and LRG Security Europe.

Franco Staino

DIRECTOR

Mr. Franco Staino is a business professional with over 40 years experience in the pharmaceutical industry. Mr. Staino has significant experience in drug safety, traceability and anti-counterfeiting measures and has designed and implemented programs for the Italy National Health Service, the Ministry of Health and the Polygraphic Institute and State Mint.

Mr. Staino currently holds multiple positions including being the control representative of Carlucci a leading company engaged in the production of self-adhesive labels for consumer goods with high specialization for the pharmaceutical sector, and President of the Board of Directors of Topharmacia, a company that deals with the integral management of pharmacies throughout Italy in order to improve their ability to provide social and commercial services, to connect industrial marketing policy to that of the pharmacy, to offer tools in able to guarantee the financial balance of the companies involved.